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Abstract
Background: Existing evidence indicates that once mature neonates with severe cardio-respiratory failure become 
eligible for Extra Corporeal Membrane Oxygenation (ECMO) their chances of intact survival are doubled if they actually 
receive ECMO. However, significant numbers survive with disability. NEST is a multi-centre randomised controlled trial 
designed to test whether, in neonates requiring ECMO, cooling to 34°C for the first 48 to 72 hours of their ECMO course 
leads to improved later health status. Infants allocated to the control group will receive ECMO at 37°C throughout their 
course, which is currently standard practice around the world. Health status of both groups will be assessed formally at 
2 years corrected age.
Methods/Design: All infants recruited to the study will be cared for in one of the four United Kingdom (UK) ECMO 
centres. Babies who are thought to be eligible will be assessed by the treating clinician who will confirm eligibility, 
ensure that consent has been obtained and then randomise the baby using a web based system, based at the National 
Perinatal Epidemiology Unit (NPEU) Clinical Trials Unit. Trial registration.
Babies allocated ECMO without cooling will receive ECMO at 37°C ± 0.2°C. Babies allocated ECMO with cooling will be
managed at 34°C ± 0.2°C for up to 72 hours from the start of their ECMO run. The minimum duration of cooling will
be 48 hours. Rewarming (to 37°C) will occur at a rate of no more than 0.5°C per hour. All other aspects of ECMO
management will be identical. Primary outcome: Cognitive score from the Bayley Scales of Infant and Toddler
Development, 3rd edition (Bayley-III) at age of 2 years (24 - 27 months).
Discussion: For the primary analysis, children will be analysed in the groups to which they are assigned, comparing the 
outcome of all babies allocated to "ECMO with cooling" with all those allocated to "ECMO" alone, regardless of 
deviation from the protocol or treatment received. For the primary outcome the analysis will compare the mean scores 
for each group of surviving babies. The rationale for this choice of primary analysis is to give a fair representation of the 
average ability of assessable children, accepting the limitation that excluding deaths might impose.
The consistency of the effect of cooling on the group of babies recruited to the trial will be explored to see whether
cooling is of particular help, or not, to specific subgroups of infants, using the statistical test of interaction. Therefore
pre-specified subgroup analyses include: (i) whether the ECMO is veno-arterial or veno-venous; (ii) whether the
child's oxygenation index at the time of recruitment is <60 or ≥ 60; (iii) initial aEEG pattern shown on the cerebral
function monitor, and (iv) primary diagnostic group.
Trial Registration: Current Controlled Trials ISRCTN72635512.
Background
Introduction
NEST is a multi-centre randomised controlled trial
designed to test whether, in neonates requiring ECMO,
cooling to 34°C for the first 48 to 72 hours of their ECMO
course leads to improved later health status. Infants allo-
cated to the control group will receive ECMO at 37°C
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Page 2 of 11throughout their course, which is currently standard
practice around the world. Health status of both groups
will be assessed formally at 2 years corrected age.
Hypothesis
Cooling neonates requiring ECMO to 34°C for the first 48
to 72 hours of their ECMO run results in improved neu-
rodevelopmental outcome at 2 years corrected age. (Note:
neonate is defined as less than or equal to 28 days of age).
Background
ECMO is an invasive method of life support used in
severe respiratory or cardio-respiratory failure. ECMO
entered clinical practice as an extension of the technology
that produced cardiopulmonary bypass. Although it has
been used in patients of all ages, relatively mature (35
weeks gestation age or more) newborn infants form by far
the largest patient group to date.
In the last 20 years ECMO has been used to support
over ten thousand neonates with severe cardio-respira-
tory failure worldwide. Despite the availability, in recent
years, of new therapies the majority of neonates who
develop the severest forms of cardio-respiratory failure
still require ECMO. The most recent evidence indicates
that ECMO is the most effective form of life support for
neonates that fulfil the eligibility criteria for ECMO both
in terms of improved survival and morbidity [1]. How-
ever, outcome data from both randomised trials and clin-
ical series indicate that ECMO eligible neonates are at
high risk of later neurodevelopmental problems. Approx-
imately 40% of survivors develop some form of impair-
ment irrespective of whether they received ECMO or
some other less invasive means of life support [2]. Data
from the UK collaborative ECMO trial indicates that 32%
of the original cohort of children in the ECMO arm sur-
vived without disability at 4 years of age compared with
14% in the conventional treatment arm [2]. Although two
thirds of the children seen at 4 years were described as
having a cognitive outcome within the normal range, the
mean general conceptual ability score was only 93, signif-
icantly below average. Specific difficulties in visiospatial
tasks as well as behavioural problems and sensory losses
were also found.
Causation of brain injury in infants who meet the criteria for 
ECMO
For most infants the precise aetiology of the neurological
damage associated with severe cardio-respiratory failure
is uncertain. Infants who meet the entry criteria for
ECMO are, by definition, relatively mature and do not
have evidence of severe neurological compromise at
birth. However, there is often a history of fetal distress,
meconium stained liquor and infection. Sub-optimal
Apgar scores and low cord pH values are common [3].
Postnatally, they may be acidotic, poorly perfused and
exposed to varying degrees of hypoxia. Severe cardio-
respiratory disease may be associated with a persistent
fetal circulation and a patent foramen ovale, leaving the
cerebral circulation vulnerable to circulating emboli and
thrombus [4]. However, the time of maximal physiologi-
cal derangement from the underlying condition leading
to the severe cardio-respiratory failure normally coin-
cides with a decision to use ECMO and the establishment
of ECMO poses a further insult to the cerebral circulation
and hence to the brain [5]. Thus the establishment of
ECMO may act as a marker for a time of "maximum risk"
for the brain and it would appear appropriate to attempt
to protect the brain at this critical period.
The pattern of brain injury and likely outcome in infants 
meeting the criteria for ECMO
The existing data [6-9] on brain imaging following
ECMO confirm the above i.e. that the predominant pat-
tern of injury is white matter infarction with cortical
involvement. Haemorrhage occurs to a lesser extent.
These observations are consistent with the fact that these
infants do not have very low Apgar scores and severe aci-
dosis and they are not thought to be encephalopathic.
Therefore it is unlikely that injury to the central grey mat-
ter will be the predominant pattern of injury. Given the
background problems these infants are exposed to, their
neurological deficits are likely to result from a more pro-
longed sub-acute insult leading to white matter and corti-
cal damage in a parasagittal distribution. Data from
studies in term infants with neonatal encephalopathy or
seizures with this pattern of damage suggest that unless
the damage is very severe, the children do not develop
cerebral palsy. However they do have delays in acquisition
of motor skills, difficulty with fine motor tasks, visual and
visuospatial difficulties, some delay in the development of
speech and language, learning and behavioural difficul-
ties and sub-optimal head growth [10-12]. Children with
focal infarction have a motor outcome consistent with the
site of injury [13,14]. The existing data on outcome in
children meeting ECMO criteria are consistent with this
description [2].
Rationale for the use of mild hypothermia
One of the most promising methods for achieving neuro-
protection is the use of mild hypothermia. This approach
has been investigated in animal studies by a number of
groups using a variety of "hypoxic-ischaemic" insults [15-
19]. These studies, including those by members of our
own group, have consistently shown benefit without
adverse side effects, even when hypothermia was applied
up to 6 hours after the injury. Reduction of body temper-
ature by 3-4°C after a cerebral insult was associated with
improved histological and long-term behavioural out-
come in both adult and newborn animals. Preliminary
clinical studies in adult humans of whole body hypo-
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suggested potential benefit in all these groups. However,
results of randomised trials in adults have shown benefi-
cial effects in relation to cardiac arrest but not head
injury [20]. Studies in human neonates who have been
subject to hypoxic-ischaemic insults suggest that the
technique is safe [21-23]. Preliminary results from the
first two randomised trials to investigate the potential for
mild hypothermia applied for 72 hours from within six
hours of birth to protect the neonatal brain after a perina-
tal hypoxic-ischaemic insult have suggested some evi-
dence of benefit [24,25]. These data suggest that neonates
with the most severe cerebral damage may be less likely to
benefit from cooling. Neonates with this type of damage
are excluded from ECMO. However, outcomes for those
with the less severe insults as assessed by pre-hypo-
thermia aEEG recordings had evidence of an improved
outcome [26]. Further randomised trials to assess the
effects of hypothermia on the long term outcome of such
infants are still on-going. It is likely that a number of such
trials will be needed to fully evaluate the potential of
hypothermia in reducing brain injury, as there is evidence
that the effectiveness of the intervention, if present, is
affected by a variety of factors such as the timing of onset
of hypothermia in relation to the insult and the degree
and duration of the hypothermia.
The focus of most animal and clinical studies into brain
damage in the relatively mature newborn has been in
relation to a hypoxic-ischaemic insult around the time of
birth leading to hypoxic-ischaemic encephalopathy. Fol-
lowing such an insult brain cells are lost in two phases:
neuronal loss may occur during or immediately following
the insult and subsequently further cells die over weeks
or months primarily as a result of apoptosis. It is this sec-
ond phase of cell loss that early mild hypothermia
appears to have the potential to influence [27]. There are
no equivalent studies to confirm that apoptosis is an
important component of the brain damage and poor out-
come noted in ECMO survivors. However, given the
nature of the illnesses these children suffer in order to
become ECMO eligible and the type and degree of physi-
ological derangement, there is clearly potential for both
types of neuronal loss described above to occur. There is
clear evidence that infants who reach ECMO eligibility
criteria have a high rate of neurodisability if they survive.
The risk for neurodevelopmental impairment is signifi-
cantly reduced if the newborn actually goes on to ECMO
but the rate of adverse outcome remains high. Whilst the
nature and timing of the brain insult(s) that lead to this
adverse outcome remain poorly understood, given the
background on which they occur, it is appropriate to for-
mally test the potential of hypothermia to reduce this
risk.
Feasibility studies for hypothermia in infants having ECMO
Although there is some information about the physiologi-
cal impact of mild hypothermia [33°C or above) data
applicable to the newborn are very limited. More infor-
mation is available in relation to moderate hypothermia
in adults but this is only helpful in identifying those
bodily functions that might be impaired by a period of
mild hypothermia [28-30]. No systematic studies have
previously been performed to assess the therapeutic
affect of mild hypothermia on patients on ECMO. There-
fore in preparatory work (funded by The British Heart
Foundation) we have investigated the feasibility and
safety of using mild hypothermia in neonates receiving
ECMO. The study population of this investigation com-
promised the following infants (note the next reduction
in temperature or increase in duration of hypothermia
only occurred after the successful completion of the pre-
vious stage):(Neonatal patients were defined as infants of
less than 28 days of age).
5 neonates maintained at 37°C throughout their ECMO
course (controls);
5 neonates maintained at 36°C for the first 12 hours of
their ECMO course;
5 neonates maintained at 35°C for the first 12 hours of
their ECMO course;
5 neonates maintained at 34°C for the first 12 hours of
their ECMO course.
5 neonates maintained at 37°C throughout their ECMO
course (controls);
5 neonates maintained at 36°C for the first 24 hours of
their ECMO course;
5 neonates maintained at 35°C for the first 24 hours of
their ECMO course;
5 neonates maintained at 34°C for the first 24 hours of
their ECMO course.
5 neonates maintained at 34°C for the first 48 hours of
their ECMO course.
The decision to use ECMO was based on standard cri-
teria and was made on clinical grounds alone (an oxygen-
ation index of 40 or more, or a PaCO2of 13 kPa or more
despite maximal non-ECMO support and with no con-
tra-indication to ECMO).
The clinical course of each infant was closely scru-
tinised but in addition a number of specific investigations
and observations were performed in relation to: blood
clotting, immune function, EEG, cardiac conduction,
oxygenator function and circuit performance.
A paper describing the first 20 patients [31] and a sec-
ond paper focusing on the next 25 patients have been
published [3]. In summary, there was no evidence that
hypothermia had an adverse impact on the acute clinical
condition of the baby. There did appear to be an effect on
cardiac conduction as measured by ECG, but this was not
clinically apparent during the baby's ECMO course.
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complications. Similarly there was no adverse effect
noted in relation to the ECMO circuit or its management.
Of particular relevance to long term outcome, tempera-
ture change had no effect on the aEEG.
Methods/Design
This is a pragmatic multi-centre randomised controlled
trial. Babies will be randomised to one of two arms:
The treatment arm in which babies will be cooled to
34°C for the first 48 to 72 hours of the ECMO run.
The control arm in which babies will undergo conven-
tional (normothermic) ECMO.
Inclusion criteria
Babies recruited to the study must meet the existing stan-
dard criteria for ECMO eligibility. These include:
• at least 35 weeks gestation;
• at least 2000 g weight;
• no uncontrolled bleeding disorder;
• no congenital or acquired CNS disorder;
• no more than 7 consecutive days of high pressure ven-
tilation prior to referral for ECMO;
• the underlying condition is potentially reversible;
• evidence of severe cardio-respiratory failure;
• less than 29 days of age.
Exclusion criteria
• All neonates referred with diaphragmatic hernia;
• All neonates receiving ECMO for post operative car-
diac support.
• All neonates who have been cooled prior to ECMO.
Among the babies with diaphragmatic hernia referred
for ECMO a number have severe pulmonary hypoplasia
incompatible with survival. These infants cannot be reli-
ably detected prior to ECMO and there is no rationale for
believing that cooling will help these infants [32]. Babies
receiving ECMO following cardiac surgery, in general, are
not comparable in terms of their risk of serious adverse
neurodevelopmental outcome.
All other infants will be eligible unless aspects of their
medical condition prevent or render them inappropriate
for ECMO.
Duration of cooling
At the time of the pilot studies underpinning this trial,
two factors were considered of particular importance
when deciding on the duration of cooling to be used as
the intervention:
1. Virtually all babies requiring ECMO have a run of at
least 48 hours (i.e. cooling for 48 hours could be used
without altering other aspects of normal ECMO manage-
ment).
2. Previous studies had found that cooling for 48 hours
could have a therapeutic effect.
However, subsequently two randomised trials of mild
cooling in infants with hypoxic-ischaemic encephalopa-
thy found cooling for 72 hours may result in improve-
ment in outcome [25,26]. Cooling for this duration has no
effect on the ECMO circuit as patients are sometimes
maintained at this temperature for prolonged periods for
reasons other than neuroprotection e.g. reducing oxygen
consumption. Although the majority of babies on ECMO
require at least 72 hours of ECMO, some babies can come
off ECMO at between 48 and 72 hours. To come off
ECMO while maintaining cooling would be technically
complex and might result in adverse consequences. How-
ever, to maintain babies on ECMO longer than they
would normally require in order to maintain cooling for
72 hours would mean exposing the baby to the on-going
risks of ECMO unnecessarily. Therefore, the duration of
the intervention in NEST will be for a minimum of 48
hours and a maximum of 72 hours. Infants will be re-
warmed before coming off ECMO.
Consent
Neonates will be recruited only after informed consent
has been obtained from the parent(s). Clearly this will
pose major logistic problems since it is planned that cool-
ing will commence at the start of the ECMO run and in
many cases there will be an urgent need to establish
ECMO. In order to optimise recruitment:
• ECMO centres involved in the study will discuss the
study with the parents of all children cared for "in house"
who are likely to need ECMO e.g. children with persistent
pulmonary hypertension and deteriorating blood gases
despite full conventional support. These discussions will
be supported by information leaflets for parents describ-
ing both ECMO and the study.
• Where neonates are "retrieved" for ECMO from other
centres the situation will be more difficult. In many cases
there will be a period (of up to 2 days) during which a
transfer for ECMO is being considered. In these circum-
stances the ECMO centre will have the opportunity to fax
ahead detailed information about the study and also brief
the local clinical team prior to any retrieval. Should the
referral for ECMO subsequently go ahead, and parents
agree to their child joining the study, formal consent can
be obtained by the routine retrieval team without undue
haste. On other occasions such referrals and transfers for
ECMO take place at short notice. On these occasions the
team will include sufficient personnel (an ECMO special-
ist, or doctor or senior nurse involved with the ECMO
programme) to allow time to be spent with the parents
both to explain the study and obtain informed consent.
At the start of the study, ECMO centres will also discuss
with clinicians at centres that have previously referred
babies for ECMO, the details of the study protocol.
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process. At the time of initial recruitment parents will
receive the Information Leaflet about the study (as well as
the leaflet explaining ECMO produced by the ECMO
centre retrieving or caring for the baby) and at that time
parents will be asked to give written consent. Where it is
not possible for parents to travel with the baby to the
ECMO centre, consent may be obtained over the tele-
phone. This will be witnessed by a second member of
staff and the Telephone Consent form completed. Both
members of staff will sign the Telephone Consent form
and on arrival at the ECMO centre parents will be asked
to add their signature to confirm their consent. Where
parents do not have a good grasp of English, unless a
good interpreter is immediately available, recruitment
should not proceed. Where a child is recruited, a follow
up conversation (using the Further Information Leaflet
about the study) should take place during the stay in the
ECMO centre. No "re consenting" is required but the
conversation and the parent's agreement to allow their
baby to continue in the study should be documented in
the medical records.
Randomisation
All infants recruited to the study will be cared for in one
of the four UK ECMO centres. Infants who require
ECMO will be transferred to these centres from across
the country. Babies who are thought to be eligible will be
assessed by the treating clinician who will confirm eligi-
bility, ensure that consent has been obtained and then
randomise the patient using the web based system, pro-
vided by the National Perinatal Epidemiology Unit
(NPEU). As soon as parental consent has been obtained,
the recruiting ECMO specialist, or delegate, will log on to
the web site and obtain the treatment allocation, which
will be either to "ECMO" or "ECMO with cooling". Mini-
misation will be used to ensure balance between the
groups with respect to the most important factors likely
to affect later outcome, one of which is the method of
cannulation (either veno-venous or veno-arterial).
ECMO management
In those babies randomised to "ECMO with cooling",
cooling will begin immediately upon initiation of the
extra-corporeal circulation. The baby's temperature will
be measured either by nasopharyngeal, rectal or urinary
electronic temperature probe. The water heater will be
adjusted to maintain the core temperature at 34°C. Once
the cooling period has passed the baby will be rewarmed
by increasing the target temperature by no more than
0.5°C every hour.
Cerebral function monitoring, using the aEEG, will be
used from the onset of ECMO to both aid clinical man-
agement and provide additional information when
assessing the outcome data.
During cooling heparin management will continue
according to institutional protocols, however, it is impor-
tant to note that the only study to use cooling for babies
on ECMO was done using the Hemochron System (ITC,
NJ, USA) and P214 tubes. The hemochron machine itself
measures the activated clotting timeat 37°C. In addition
none of the babies in this study received amicar, which
should therefore not be administered during the NEST
study. If an anti-fibrinolytic drug is indicated it is recom-
mended that aprotinin is used with a loading dose of 1
ml/kg followed by an infusion of 1 ml/kg/hr.
Outcomes
Primary outcome
Cognitive score from the Bayley scales of Infant and Tod-
dler Development, 3rd edition (Bayley-III) [33] at age of 2
years (24 - 27 months).
Secondary outcomes
• Death
• Neurological optimality score [34,35]
• Gross and fine motor score from the Bayley-III [33]
• Cerebral Palsy
• Gross motor function classification score (GMFCS)
[36]
• Seizures requiring regular anticonvulsant treatment
• Visual difficulties not corrected by spectacles
• Hearing difficulties requiring aids
• Language - expressive and receptive scores from the
Bayley-III [33]
• Parent Report of Children's Abilities, (PARCA-R) [37-
39]
• Infant Characteristics Questionnaire [40]
• The Brief Infant-Toddler Social and Emotional
Assessment (BITSEA) [41]
• Measures of growth - height, weight and head circum-
ference [10]
A child will be considered to be functioning within the
normal range for age if their results are within the normal
range for all Bayley scores and they have a normal neuro-
logical examination, normal vision (including with spec-
tacles) and normal hearing (no aids).
Neurodevelopmental tools and age at assessment
• The Bayley Scales at 2 years corrected age [33]. The
Bayley Scales of Infant and Toddler Development are
widely used for assessing development in young children.
The scales have been recently revised and re-stan-
dardised and the administered scales are now in sepa-
rated into three domains: cognition, language and motor
(Bayley-III). For all three domains a score of 100 is aver-
age and scores of 115 and 85 represent respectively one
standard deviation above and below the mean.
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replaced the Mental Development Index (MDI) from the
BSID-II, has the advantage of being relatively language
free and will be used as the primary outcome measure.
Language will be assessed using the language scale from
the Bayley-III and also from a parent report (PARCA-R)
[37-39]. The scales have good psychometric properties
and reliability in the clinical setting. In a group of 850
three-year old term children in the UK, the BSID-II mean
MDI was within 1 point of the US standardisation mean
suggesting high relevance to the UK population [42]. The
Bayley-III is currently being tested to check for UK
norms and being using in several research contexts in the
UK. Current outcome data from ECMO children finds
few with very low cognitive levels and hence it should be
possible to give a score to most children. Randomised tri-
als of mild cooling as a neuroprotection measure follow-
ing perinatal hypoxic-ischaemia have employed the
Bayley score at around 2 years as a primary outcome [24].
Additionally the Bayley scales have been used for the fol-
low up of preterm infants (EPICure [42] and PRO-
GRAMS) at 2 years corrected age. Thus there is
increasingly wide experience of using the Bayley scales in
the UK. Cognitive abilities will also be assessed using the
PARCA-R as a parent report measure. The PARCA was
developed by Saudino et al [37] for use in term-born
infants at two years, with additional items (PARCA-R) to
assess non-verbal cognitive skills at a lower developmen-
tal level (validated by Johnson et al in preterms [38,39]).
• A formal clinical and neurological examination at 2
years corrected age [34,35]. This neurological exam gives
an "optimality score" with a maximum score 78 (3 × 26
different items). The items are grouped into those relat-
ing to cranial nerve function (five), posture (six), tone
(eight), movements (two) and reflexes (five). This score
has been standardised to 18 months [34] but can be used
in two year olds [43]. A functional description of the
child's motor abilities will be recorded and whether they
are thought to have a diagnosis of cerebral palsy. Motor
function will also be assessed in term of gross and fine
motor skills using the motor scale from the Bayley-III
[33] and classified using the Gross Motor Function Clas-
sification score [36].
• Head circumference will also be measured. Centiles
will be calculated related to neonatal head circumference
centile [10]. Height and weight will also be measured.
• The administered Bayley scales will not give informa-
tion about all aspects of development that are of concern
in this group of infants. The existing data on outcome
from ECMO eligible infants showed that 71% of survivors
in both ECMO and control groups have no signs of
impairment at one year of age; by age four years this pro-
portion had fallen to 20% and 11.4% respectively [2] with
overall cognitive function in the low normal range and
specific difficulties with visuospatial tasks, behaviour and
sensory modalities. Specific items in the Bayley-III scales
assessing fine motor skills and visuospatial function will
be looked at in detail. Given testing-time constraints it
was felt that as the Bayley-III scales test these domains in
more depth than the BSID-II we would not add further
visuospatial testing as we originally suggested.
• Issues of behavioural problems (highlighted in the 4
year outcome study of the original ECMO trial cohort)
will be assessed using Characteristics Questionnaire
(ICQ) [40] and the BITSEA [41], parental report ques-
tionnaires. The ICQ assesses infant temperament and the
BITSEA social-emotional and behavioural problems.
Data on short-term outcomes (up to discharge from
hospital) will be collected during the babies' hospital stay.
Major morbidity at 2 years corrected age will be assessed
by a paediatrician, masked to study allocation.
Long-term follow-up at 5 years
However, it is recognised that the detection of many sub-
tle deficits, particularly in the fields of behaviour, atten-
tion and cognition, may be unreliable at the age of two
years. These deficits have major implications for educa-
tional achievement and social functioning. We therefore
hope to be able to perform a detailed, standardised clini-
cal examination and assessment of neurological, develop-
mental, cognitive and behavioural function at the age of
five years. Families will be informed during recruitment
of our intention to follow up their children again.
Sample Size
Sample size estimates have been made based on what are
considered to be potentially clinically important differ-
ences in the cognitive scores from the Bayley-III at two
years corrected age.
Table 1 gives a range of total sample sizes based on vari-
ations in the mean and standard deviation of these scores.
The first of these options (requiring the recruitment of
118 infants) offers a realistic recruitment target whilst
also giving 90% power to detect a significant difference
between the two arms (at a two-tailed 5% level of signifi-
cance). The choice of 85 and 95 as the two Bayley scores
on which to derive the trial size is based on: a) what might
be considered a clinically significant difference and b)
existing knowledge of ECMO survivors [2,9].
Feasibility
We estimate that it should be feasible to recruit this num-
ber of infants in 30 months as:
• all 4 UK ECMO centres have agreed to join the study.
• It is estimated that 70 suitable neonates will be
referred to these centres per year (67% recruitment to the
study is therefore required).
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Demographic factors and clinical characteristics will be
summarised with counts (percentages) for categorical
variables, mean (standard deviation [SD]) for normally
distributed continuous variables, or median (interquartile
[IQR] or entire range) for other continuous variables.
Comparative statistical analysis will entail calculating
the mean difference plus 95% confidence interval [CI] for
the primary outcome (likewise for other normally distrib-
uted continuous outcomes), the median difference (plus
95% CI) for skewed continuous variables and the risk
ratio (plus 95% CI) for secondary outcomes which are
categorical.
For the primary analysis, patients will be analysed in
the groups to which they are assigned, comparing the
outcome of all babies allocated to "ECMO with cooling"
with all those allocated to "ECMO" alone, regardless of
deviation from the protocol or treatment received. For
the primary outcome (the cognitive score from the Bay-
ley-III at age 2 years), the analysis will compare the mean
scores for each group of surviving babies. The rationale
for this choice of primary analysis is to give a fair repre-
sentation of the average ability of assessable children,
accepting the limitation that excluding deaths might
impose. There is potential for bias, but only in the pres-
ence of high and/or differential mortality between the
groups. An adjusted analysis will be performed for the
primary outcome to investigate the impact of stratifica-
tion/known prognostic factors.
The primary analysis is therefore of survivors. Sensitiv-
ity analyses will be used to assess the robustness of the
results and the impact of missing data. Missing primary
outcomes data for surviving children arise due to (i) logis-
tical reasons, (ii) parental wishes, (iii) children being
untestable for behavioural reasons or (iv) children being
too severely disabled to be assessed using the Bayley-III
scales. Strategies employed will include:
1. imputing arbitrary scores
2. imputing scores using single imputation by using
repeated random sampling from a distribution (mean =
100 SD = 15) to create a sample of scores per missing
value e.g. 5, depending on the individual circumstances
and impute the appropriate summary statistic i.e. the
median.
For any children that we cannot see:
• but where we have some indication from parental
questionnaire of no neurodevelopmental problems, we
will sample randomly from those scores of children who
score above -2 SDs of the mean
• but where we have no information regarding the child
or there is an indication of a neurodevelopmental prob-
lem, then we would sample randomly from the entire
range of scores within our study population
For any children we do see:
• but for whom we are unable to obtain a cognitive
score on the Bayley-III because of behavioural difficulties,
but who are motorically competent, we will sample from
between 2 and 3 SDs below the mean
• but are too severely disabled to test, we will sample
from between 3 and 4 SDs below the mean
NB. imputing missing values using multiple imputation
techniques based on values of the population distribution
(taking into account the child's most important charac-
teristics) would be preferable, but the sample size in this
study is too small.
A further sensitivity analysis will use rank based statis-
tical methods; typically more conservative, but valid
given that we are at the extremes of the distribution.
The consistency of the effect of cooling on the group of
babies recruited to the trial will be explored to see
whether cooling is of particular help, or not, to specific
subgroups of infants, using the statistical test of interac-
tion. Therefore pre-specified subgroup analyses include:
(i) whether the ECMO is veno-arterial or veno-venous;
(ii) whether the child's oxygenation index at the time of
recruitment is <60 or ≥ 60; (iii) initial aEEG pattern
shown on the cerebral function monitor, and (iv) primary
diagnostic group. Subgroup analysis will be performed on
the following outcomes (a) the primary outcome, (b)
vision, (c) hearing and (d) neurological status. The sub-
group analyses will be interpreted as exploratory.
Table 1: Sample size estimates
Assumed mean scores of the 
two arms
Assumed SD of Bayley-III 
cognitive scores
Total sample size required 
for 90% power
Number needed to be 
recruited assuming 80% 
survival to 2 years
85 & 95 15 94 118
85 & 95 10 42 53
90 & 95 10 168 210
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Ethics approval was granted by the Trent Research Ethics
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Organisation
Project management group
A core team of individuals will liaise regularly regarding
the general progress and management of the study. This
will normally occur by teleconference every 6 weeks.
Trial Steering Committee meetings will occur annually. A
central co-ordinating centre based at the National Perina-
tal Epidemiology Unit will be responsible for organising
these meetings as well as:
• General oversight and compliance with procedures;
• Data management;
• Data analysis;
• Servicing the Data Monitoring Committee;
• Organising follow up appointments and maintaining
contacts with families via newsletters and birthday cards.
Trial Steering Committee
The Trial Steering Committee will provide overall super-
vision of the trial on behalf of the British Heart Founda-
tion. Its terms of reference are:
• To monitor and supervise the progress of the NEST
study towards its interim and overall objectives;
• To review at regular intervals relevant information
from other sources (related studies);
• To consider the recommendations of the Data Moni-
toring Committee;
• In the light of 1, 2 and 3 above to inform the British
Heart Foundation of progress of the study;
• To advise the British Heart Foundation on publicity
and the presentation of all aspects of the study.
The membership is:
Professor Andrew Wilkinson (Chair), Consultant
Paediatrician, John Radcliffe Hospital, Oxford.
Professor Marianne Thoresen, Professor of Neonatal
Neuroscience, University of Bristol.
Dr Clare Snowdon, Research Fellow, LSHTM, Lon-
don
Ms Pauline Fellows, NSC Neonatal Project Facilitator,
Addenbrooke's Hospital, Cambridge
Ms Farrah Pradhan, Family Support Co-ordinator,
Bliss, London
Dr Mary Montgomery, Consultant in Retrieval and
Critical Care, Children's Acute Transport Services
and the Royal Brompton Hospital PICU, London
Professor David Field (Chief Investigator), Consultant
Paediatrician, Dept of Health Sciences, University of
Leicester
Professor Peter Brocklehurst (Investigator), Director,
NPEU, Oxford
Data Monitoring Committee
This will be independent of the study organisers and will
meet annually. During the period of recruitment to the
study, interim analyses will be supplied, in strict confi-
dence, to the DMC, together with any other analyses the
DMC may request. The data will be supplied to the Chair
of the DMC as frequently as she requests. Meetings of the
committee will be arranged periodically, as considered
appropriate by the Chair. In the light of interim data, and
other evidence from relevant studies (including updated
overviews of the relevant randomised controlled trials),
the DMC will inform the Steering Committee, if in their
view i) there is proof beyond reasonable doubt that the
data indicate that any part of the protocol under investi-
gation is either clearly indicated or contra-indicated,
either for all infants or for a particular subgroup of trial
participants or ii) it is evident that no clear outcome will
be obtained.
Appropriate criteria for proof beyond reasonable doubt
cannot be specified precisely. A difference of at least 3
standard errors in the interim analysis of a major end-
point may be needed to justify halting, or modifying,
such a study prematurely. If this criterion were to be
adopted, it would have the practical advantage that the
exact number of interim analyses would be of little
importance. One interim analysis is planned for each year
of recruitment, as well as one analysis six months after
recruitment has stopped. These analyses will concentrate
on outcomes at hospital discharge, as many of these
babies will not have had their two-year assessments per-
formed at the time of the interim analyses. Unless modifi-
cation or cessation of the protocol is recommended by
the DMC, the Trial Steering Committee, collaborators
and administrative staff (except those who supply the
confidential information) will remain ignorant of the
results of the interim analysis. Collaborators and all oth-
ers associated with the study may write through the
NEST Co-ordinating Centre to the DMC to draw atten-
tion to any concern they may have about the possibility of
harm arising from the treatment under study, or about
any other matters that may be relevant.
The membership is:
Professor Diana Elbourne (Chair), Prof. Health Care
Evaluation, LSHTM, London
Dr Duncan Macrae, Director of PIC, Royal Brompton
Hospital, London
Professor Henry Halliday, Consultant Paediatrician,
Royal Maternity Hospital, Belfast
Professor Richard Cooke, Consultant Paediatrician,
Liverpool Women's Hospital.
Professor Neil Marlow, Professor of Neonatal Medi-
cine, UCL Institute For Women's Health, London
Professor Linda Franck, Prof. and Chair Children's
Nursing Research Centre for Nursing and Allied
Field et al. BMC Pediatrics 2010, 10:24
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Hospital, London
Serious Adverse Events and Suspected Unexpected
Serious Adverse Reaction reporting
Assessment of Safety
Safety monitoring has been delegated by the Sponsor
(University Hospitals of Leicester NHS Trust, of Leices-
ter) to the National Perinatal Epidemiology Unit (NPEU)
at the University of Oxford.
Safety will be assessed continuously during each baby's
stay in the ECMO unit. Any adverse events which require
expedited reporting will follow the system outlined
below.
Other outcomes, which may also be considered safety
outcomes, such as early neonatal morbidity, but which
are anticipated outcomes for this group of babies, will be
captured on study specific data collection forms.
Expected Adverse Drug Reactions
No adverse drug reactions will occur as the study inter-
vention is not a drug.
Expected Serious Adverse Events (SAEs)
The following are serious adverse events that could be
reasonably expected for this group of babies during the
course of the study:
• Death
• Major ECMO circuit complications such as oxygen-
ation failure of line rupture
• Major cerebral haemorrhages after trial entry
• Major haemorrhage requiring transfusion
For the purposes of this study these SAEs require
immediate reporting.
Serious Adverse Reactions (SARs)
Although the study intervention is not a drug, the only
theoretically possible recognised adverse reactions/
events associated with this treatment are:
• Deranged clotting arising during cooling period
• Evidence of impaired immunity arising during cooling
period
Causality Assessment
All cases judged by either the reporting medically quali-
fied person or the Chief Investigator as having a reason-
able suspected causal relationship to the treatment
qualify as an Adverse Event.
Expedited/immediate reporting of safety events
All expected SAEs or SARs described above must be
reported to the Trial Co-ordinating Centre within 10 days
of discovery or notification of the event, this will be
immediately referred to the Chief Investigator or his dele-
gated deputy. If urgent safety measures will be required as
a result of an SAE or SAR then the event or reaction must
be reported within one working day of discovery or noti-
fication of the event to the Trial Co-ordinating Centre. A
Standard Operating Procedure (SOP) outlining the
reporting procedure for clinicians will be provided on the
reverse of the SAE form. An SOP will also be available as
part of the Trial Specific SOPs which will outline the
reporting procedure for the Trial Co-ordinating Centre.
All SAE and SAR information must be recorded on an
SAE form and faxed to the Chief Investigator or their del-
egated Deputy. Additional information received for a case
(follow-up or corrections to the original case) needs to be
detailed on a new SAE and SAR form and faxed to the
Chief Investigator or their delegated deputy.
The severity of events will be assessed on the following
scale: 1 = mild, 2 = moderate, 3 = severe. The relationship
of SAEs or SARs to the study intervention will be
assessed according to the definition provided above.
The Trial Co-ordinating Centre will report all SAEs and
SARs to the Ethics Committee concerned using the SAE
report form for non-CTIMPs, available from the NRES
website. In addition a copy of the SAE or SAR will be for-
warded to the Chair of the Data Monitoring Committee.
The Chair will also be provided with a document detail-
ing all previous SAEs and SARs. The Chief Investigator
will also inform all investigators concerned of relevant
information about SAEs and SARs that could adversely
affect the safety of participants.
In addition to the expedited reporting above, the Chief
Investigator shall submit, once a year throughout the
clinical trial, or on request, a safety report to the Ethics
Committee.
Reporting procedures for all adverse events
All adverse events (AEs) occurring during the study
observed by the investigator or reported by the partici-
pant, whether or not attributed to study intervention, will
be reported on the data collection form. AEs considered
to be related to the study intervention by the investigator
will be followed up until resolution or the event is consid-
ered stable. The investigator may be asked to provide fol-
low-up information.
All related AEs that result in a participant's withdrawal
from the study or are present at the end of the study,
should be followed up until a satisfactory resolution
occurs.
It will be left to the investigator's clinical judgment
whether or not an AE is of sufficient severity to require
the participant's removal from treatment. A participant
may also be voluntarily withdrawn from treatment due to
what the attending clinician or the parents perceive to be
an intolerable AE.
Publication policy
The Chief Investigator will co-ordinate dissemination of
data from this study. All publications using data from this
study to undertake original analyses will be submitted to
the Trial Steering Committee (TSC) for review before
release.
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Page 10 of 11To safeguard the scientific integrity of the trial, data
from this study will not be presented in public before the
main results are published without the prior consent of
the TSC. The success of the trial depends on a number of
neonatal ECMO specialists, intensivists and parents. For
this reason, chief credit for the results will not be given to
the committees or central organisers, but to all who have
collaborated and participated in the study. Acknowledge-
ment will include all local co-ordinators and collabora-
tors, members of the trial committees, the Trial Co-
ordinating Centre and trial staff. Authorship at the head
of the primary results paper will take the form "The
NEST Study Collaborative Group". This avoids giving
undue prominence to any individual. All contributors to
the study will be listed at the end of the report, with their
contribution to the study identified.
Those responsible for other publications reporting spe-
cific aspects of the study may wish to utilise a different
authorship model, such as " [name], [name] and [name]
on behalf of the NEST Study Collaborative Group". Deci-
sions about authorship of additional papers will be dis-
cussed and agreed by the trial investigators and the TSC.
Parents will be sent a summary of the final results of the
study unless they have indicated previously that they do
not wish to receive such a summary. Opportunities to opt
out from receiving information about the progress of the
study and/or a summary of the results will be offered
periodically with the parents' newsletters. The summary
will contain a reference to the full paper. A copy of the
journal article will be available on request from the
NPEU.
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